[1]陈晓喆,姚磊,董艺丹,等.升陷利水方治疗慢性心力衰竭气虚水饮证疗效研究[J].陕西中医,2026,(2):190-195.[doi:DOI:10.3969/j.issn.1000-7369.2026.02.008]
　CHEN Xiaozhe,YAO Lei,DONG Yidan,et al.Research on therapeutic effect of Shengxian Lishui formula in treating Qi deficiency and water retention syndrome of chronic heart failure[J].,2026,(2):190-195.[doi:DOI:10.3969/j.issn.1000-7369.2026.02.008]
点击复制

升陷利水方治疗慢性心力衰竭气虚水饮证疗效研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年2期
页码:
190-195
栏目:
临床研究
出版日期:
2026-02-05

文章信息/Info

Title:
Research on therapeutic effect of Shengxian Lishui formula in treating Qi deficiency and water retention syndrome of chronic heart failure
作者:
陈晓喆; 姚磊; 董艺丹; 李建华; 桂明泰; 芦波; 周训杰; 王明珠; 符德玉
（上海中医药大学附属岳阳中西医结合医院心病科，上海 200437）
Author(s):
CHEN Xiaozhe; YAO Lei; DONG Yidan; LI Jianhua; GUI Mingtai; LU Bo; ZHOU Xunjie; WANG Mingzhu; FU Deyu
（Yueyang Integrated Traditional Chinese and Western Medicine Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China）
关键词:
慢性心力衰竭; 气虚水饮证; 升陷利水方; 左室射血分数; 葶苈大枣泻肺汤; 射血分数降低
Keywords:
Chronic heart failure; Qi deficiency and water retention; Shengxian Lishui formula; Left ventricular ejection fraction; Tingli Dazao Xiefei decoction; Heart failure with reduced ejection fraction
分类号:
R 541.6
DOI:
DOI:10.3969/j.issn.1000-7369.2026.02.008
文献标志码:
A
摘要:
目的：探索升陷利水方对慢性心力衰竭气虚水饮证患者的临床疗效。方法：采用随机对照优效性研究，纳入诊断为心衰的气虚水饮证患者94例，随机分为治疗组47例和对照组47例，干预8周，对照组采用规范西药治疗，治疗组在对照组基础上加用升陷利水方治疗，评估两组方法及治疗前后的临床疗效、N-末端前B型钠利尿肽（NT-proBNP）、心超结构及功能、中医证候积分，明尼苏达生活量表（MLHFQ）积分、血压控制达标情况及安全性指标。结果：两组治疗后在临床疗效、NT-proBNP、左室射血分数（LVEF）、左心室缩短分数（FS）、中医证候积分、MLHFQ积分改善均优于治疗前，且治疗组优于对照组（均P＜0.05）。治疗组较对照组、治疗前血压控制达标率均改善（P＜0.05），两组在安全性指标方面比较，差异无统计学意义（P＞0.05）。结论：升陷利水方治疗慢性心力衰竭能有效改善患者心脏功能、减轻气虚水饮症状、提高患者生活质量，改善血压达标率，提高心衰临床疗效。
Abstract:
Objective:To explore clinical efficacy of Shengxian Lishui formula in patients with chronic heart failure and Qi deficiency with water retention syndrome.Methods:A randomized controlled superiority trial was conducted,including 94 patients diagnosed with heart failure and Qi deficiency with water retention syndrome.They were randomly divided into a treatment group of 47 cases and a control group of 47 cases.The intervention lasted for 8 weeks.The control group was treated with standardized Western medicine,while the treatment group was treated with Shengxian Lishui formula on the basis of the control group.The clinical efficacy,N-terminal pro-B-type natriuretic peptide (NT-proBNP),echocardiographic structure and function,TCM syndrome score,MLHFQ score,blood pressure control rate and safety indicators were evaluated before and after treatment in both groups.Results:After treatment,both groups showed significant improvements in clinical efficacy,NT-proBNP,left ventricular ejection fraction (LVEF),left ventricular fractional shortening (FS),TCM syndrome score,and MLHFQ score compared with before treatment (all P＜0.05),and the treatment group was superior to the control group.The blood pressure control rate in the treatment group was significantly improved compared with the control group and before treatment (P＜0.05).There was no significant difference in safety indicators between the two groups (P＞0.05).Conclusion:Shengxian Lishui formula can effectively improve cardiac function,alleviate Qi deficiency with water retention symptoms,improve the quality of life of patients with chronic heart failure,increase the blood pressure control rate,and improve the clinical efficacy of heart failure.

参考文献/References:

[1]中国心血管健康与疾病报告2024概要[J].中国循环杂志,2025,40(6):521-559.
[2]SAVARESE G,BECHER P M,LUND L H,et al.Global burden of heart failure:A comprehensive and updated review of epidemiology[J].Cardiovasc Res,2023,118(17):3272-3287.
[3]HEIDENREICH P A,BOZKURT B,AGUILAR D,et al.2022 AHA/ACC/HFSA guideline for the management of heart failure:A report of the american college of Cardiology/American heart association joint committee on clinical practice guidelines[J].Circulation,2022,145(18):e895-e1032.
[4]OSTROMINSKI J W,HIRJI S,BHATT A S,et al.Cost and value in contemporary heart failure clinical guidance documents[J].JACC Heart Fail,2022,10(1):1-11.
[5]WANG H,CHAI K,DU M,et al.Prevalence and incidence of heart failure among urban patients in China:A national population-based analysis[J].Circ Heart Fail,2021,14(10):e008406.
[6]张超,杜宗礼,李正兰,等.加味升陷汤对气虚水停型慢性心力衰竭患者的临床疗效[J].中成药,2023,45(2):690-692.
[7]王华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-89.
[8]李金根,徐浩.慢性心力衰竭中西医结合诊疗专家共识:亮点与解读[J].中国中西医结合杂志,2016,36(2):142-145.
[9]国家中医药管理局.中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002:72-84.
[10]中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等.中国心力衰竭诊断和治疗指南2024[J].中华心血管病杂志,2024,52(3):235-275.
[11]罗良涛,付帮泽,郭淑贞,等.中医古籍中的“心衰”及其与心力衰竭的关系[J].中医杂志,2014,55(6):532-534.
[12]王滢迪,何竹青,李小茜,等.心力衰竭中医病证探析[J].中医文献杂志,2023,41(4):61-63.
[13]张锡纯.医学衷中参西录第五期医论医话[M].北京:中国医药科技出版社,2014：25-26.
[14]马玉龙,史鑫鑫,陈晓喆,等.基于大气下陷理论探讨升陷汤在慢性心力衰竭中的应用[J].陕西中医,2021,42(8):1100-1102，1107.
[15]赵洁,王欢欢,欧阳意,等.基于网络药理学及质谱技术的葶苈大枣泻肺汤抗心力衰竭的有效成分发现及作用机制分析[J].中国实验方剂学杂志,2021,27(8):151-160.
[16]张宁,王新陆,王永霞.葶苈大枣泻肺汤治疗心力衰竭的理论与应用研究探讨[J].中医研究,2022,35(11):9-13.
[17]敖玉涵,苏嘉楠,李京,等.8种中医经典方剂治疗慢性心力衰竭的网状Meta分析[J].世界中医药,2024,19(14):2128-2139.
[18]黄娟,黄湘宁,王屹菲,等.左归降糖舒心方调控TLR4/NF-κB/NLRP3通路抑制H9C2心肌细胞炎性损伤机制[J].陕西中医,2025,46(11):1454-1461.
[19]张可滢,万世英,张恺.基于网络药理学和细胞实验探讨参附方对心力衰竭能量代谢的改善作用[J].中成药,2025,47(10):3444-3450.
[20]谢成志,张莹,付畅,等.人参-三七总皂苷通过促进巨自噬抑制ISO诱导的H9c2细胞肥大及损伤[J].中国中药杂志,2025,50(7):1841-1849.
[21]刘嘉懿,石玉琳,屠立平,等.非小细胞肺癌不同证型疗效组舌象随时间变化的特征研究[J].中国中医基础医学杂志,2025,31(3):474-480.
[22]乔善鑫,陈培峰,魏海燕,等.应用广义评估方程评价肤痒清凝胶治疗儿童湿疹的疗效[J].儿科药学杂志,2025,31(2):40-44.
[23]王帅,赵志强,王贤良,等.芪参益气滴丸治疗缺血性心力衰竭的多中心、前瞻性队列研究[J].中医杂志,2022,63(7):635-643.
[24]乔利杰,李彬,彭广操,等.益气活血方及其拆方治疗冠心病心力衰竭气虚血瘀证的双盲随机对照试验[J].中华中医药杂志,2023,38(2):881-886.
[25]周梦雪,张璇,葛昭,等.中医药对血压双向调节的理论及机制探析[J].亚太传统医药,2025,21(10):206-210.

相似文献/References:

[1]杨自生,金 琪,简立国.参苓养心汤治疗慢性心衰的疗效及对心功能、活动耐力、 NTProBNP、hsCRP的影响*[J].陕西中医,2019,(2):167.
　YANG Zisheng,JIN Qi,JIAN Liguo..The effect of Shenling Yangxin decoction on chronic heart failure and its effect on cardiac function，activity endurance，NTProBNP and hsCRP[J].,2019,(2):167.
[2]孙 哲,杨 默,石宗华.丹参多酚酸盐与丹参酮治疗慢性心力衰竭临床研究[J].陕西中医,2019,(5):591.
　SUN Zhe,YANG Mo,SHI Zonghua..Clinical effect and mechanism of salvianolate and Tanshinone in the treatment of chronic heart failure[J].,2019,(2):591.
[3]向宗兴,拓 文,仇卫峰,等.黄芪保心汤配合西药治疗慢性心力衰竭临床研究*[J].陕西中医,2019,(8):1085.
　XIANG Zongxing,TUO Wen,QIU Weifeng,et al.Clinical value of Huangqi Baoxin decoction combined with western medicine in the treatment of chronic heart failure[J].,2019,(2):1085.
[4]尚加芬.参芪附仙饮联合盐酸曲美他嗪片辨治慢性心力衰竭心肾阳虚证临床研究[J].陕西中医,2020,(1):38.
[5]陈宗伟,沈志涛,郑振国,等.芪苈强心胶囊配合保元汤加减治疗慢性心力衰竭临床研究*[J].陕西中医,2020,(2):191.
　CHEN Zongwei,SHEN Zhitao,ZHENG Zhenguo,et al.Observation on the effect of Qili Qiangxin capsules assist Baoyuan decoction in the treatment of chronic heart failure[J].,2020,(2):191.
[6]凌 望,孙思明,王璐玲,等.温阳益气活血方改善慢性心力衰竭患者生活质量临床研究*[J].陕西中医,2020,(5):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
　LING Wang,SUN Siming,WANG Luling,et al.A Study on the quality of life about Wenyang Yiqi Huoxue therapy in the treatment of chronic heart failure[J].,2020,(2):621.[doi:DOI:10.3969/j.issn.10007369.2020.05.019]
[7]朱 杰,林兆奋△,胡 聃,等.中西医结合治疗慢性心力衰竭研究进展*[J].陕西中医,2020,(9):1342.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.046]
[8]刘 薇,张玉焕,李 争.芪参益气滴丸对老年气虚血瘀型心力衰竭患者心肌保护、炎症状态的影响[J].陕西中医,2021,(1):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
　LIU Wei,ZHANG Yuhuan,LI Zheng.Effects of Qishen Yiqi dropping pills on myocardial protection,inflammatory state and serum cell adhesion molecule level in elderly patients with heart failure caused by qi deficiency and blood stasis[J].,2021,(2):37.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.008]
[9]黄光明.理中汤加减治疗慢性心力衰竭及对患者血清BNP、IL-10及NOS水平的影响研究[J].陕西中医,2021,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
　HUANG Guangming.Modified Lizhong decoction on clinical symptoms and levels of serum BNP,IL-10 and NOS in patients with chronic heart failure[J].,2021,(2):159.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.006]
[10]胡 芳,谭明娜,谭小娥,等.加味五苓散联合西药治疗慢性心力衰竭疗效及对患者心功能、纤维化指标、炎性因子水平的影响[J].陕西中医,2021,(2):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]
　HU Fang,TAN Mingna,TAN Xiao'e,et al.Effects of modified Wuling powder combined with western medicine on levels of cardiac function,fibrosis indicators and inflammatory factors in patients with chronic heart failure[J].,2021,(2):167.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.008]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82174130，82274262）；上海市科技创新行动计划项目（23Y31920203）；上海市科学技术委员会项目（LYSHT2021-11190402）
更新日期/Last Update: 2026-02-09